Temirak A - Search Results

1

Irreversible Antagonists for the Adenosine A_2B Receptor.

Temirak A, Schlegel JG, Voss JH, Vaaßen VJ, Vielmuth C, Claff T, Müller CE. Temirak A, et al. Molecules. 2022 Jun 13;27(12):3792. doi: 10.3390/molecules27123792. Molecules. 2022. PMID: 35744918 Free PMC article.

2

A_2B Adenosine Receptor Antagonists with Picomolar Potency.

Jiang J, Seel CJ, Temirak A, Namasivayam V, Arridu A, Schabikowski J, Baqi Y, Hinz S, Hockemeyer J, Müller CE. Jiang J, et al. Among authors: temirak a. J Med Chem. 2019 Apr 25;62(8):4032-4055. doi: 10.1021/acs.jmedchem.9b00071. Epub 2019 Apr 15. J Med Chem. 2019. PMID: 30835463

3

Preliminary Evidence of the Potent and Selective Adenosine A2B Receptor Antagonist PSB-603 in Reducing Obesity and Some of Its Associated Metabolic Disorders in Mice.

Kotańska M, Dziubina A, Szafarz M, Mika K, Bednarski M, Nicosia N, Temirak A, Müller CE, Kieć-Kononowicz K. Kotańska M, et al. Among authors: temirak a. Int J Mol Sci. 2022 Nov 3;23(21):13439. doi: 10.3390/ijms232113439. Int J Mol Sci. 2022. PMID: 36362227 Free PMC article.

4

Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents.

Temirak A, Shaker YM, Ragab FA, Ali MM, Ali HI, El Diwani HI. Temirak A, et al. Eur J Med Chem. 2014 Nov 24;87:868-80. doi: 10.1016/j.ejmech.2014.01.063. Epub 2014 Feb 1. Eur J Med Chem. 2014. PMID: 24576797

5

Bis-pharmacophore of cinnamaldehyde-clubbed thiosemicarbazones as potent carbonic anhydrase-II inhibitors.

Rasool A, Batool Z, Khan M, Halim SA, Shafiq Z, Temirak A, Salem MA, Ali TE, Khan A, Al-Harrasi A. Rasool A, et al. Among authors: temirak a. Sci Rep. 2022 Sep 27;12(1):16095. doi: 10.1038/s41598-022-19975-y. Sci Rep. 2022. PMID: 36167735 Free PMC article.

6

Rational drug design for identifying novel multi-target inhibitors for hepatocellular carcinoma.

Temirak A, Abdulla M, Elhefnawi M. Temirak A, et al. Anticancer Agents Med Chem. 2012 Nov;12(9):1088-97. doi: 10.2174/187152012803529718. Anticancer Agents Med Chem. 2012. PMID: 22583422

7

Synthesis, biological evaluation, and docking studies of new 2-furylbenzimidazoles as anti-angiogenic agents: part II.

Temirak A, Shaker YM, Ragab FA, Ali MM, Soliman SM, Mortier J, Wolber G, Ali HI, El Diwani HI. Temirak A, et al. Arch Pharm (Weinheim). 2014 Apr;347(4):291-304. doi: 10.1002/ardp.201300356. Epub 2014 Feb 5. Arch Pharm (Weinheim). 2014. PMID: 24497234

8

Synthesis and evaluation of novel xanthene-based thiazoles as potential antidiabetic agents.

Naseem S, Shafiq Z, Taslimi P, Hussain S, Taskin-Tok T, Kisa D, Saeed A, Temirak A, Tahir MN, Rauf K, El-Gokha A. Naseem S, et al. Among authors: temirak a. Arch Pharm (Weinheim). 2023 Jan;356(1):e2200356. doi: 10.1002/ardp.202200356. Epub 2022 Oct 11. Arch Pharm (Weinheim). 2023. PMID: 36220614

9

New quinazolone-sulfonate conjugates with an acetohydrazide linker as potential antimicrobial agents: design, synthesis and molecular docking simulations.

Kassem AF, Ragab SS, Omar MA, Altwaijry NA, Abdelraof M, Temirak A, Saleh A, Srour AM. Kassem AF, et al. Among authors: temirak a. RSC Adv. 2025 Jan 13;15(2):1033-1048. doi: 10.1039/d4ra07563c. eCollection 2025 Jan 9. RSC Adv. 2025. PMID: 39807202 Free PMC article.

10

Barbiturate-sulfonate hybrids as potent cholinesterase inhibitors: design, synthesis and molecular modeling studies.

Kassem AF, Omar MA, Temirak A, El-Shiekh RA, Srour AM. Kassem AF, et al. Among authors: temirak a. Future Med Chem. 2024 Aug 17;16(16):1615-1631. doi: 10.1080/17568919.2024.2366158. Epub 2024 Jul 16. Future Med Chem. 2024. PMID: 39011621

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters